Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nexalin Technology, Inc. ( (NXL) ) just unveiled an update.
On January 23, 2026, Nexalin Technology, Inc. reported that it received a January 21 notification from Nasdaq indicating the company is no longer in compliance with the exchange’s US$1.00 minimum bid price requirement, after its shares traded below that threshold for 30 consecutive business days. Nexalin has been granted until July 20, 2026 to restore compliance by maintaining a closing bid price of at least US$1.00 for a minimum of 10 straight trading sessions; its shares will continue to trade under the NXL ticker in the meantime, while the company monitors its stock price and evaluates operational and financial measures to support its valuation, stating it is not currently considering a reverse stock split, and faces the possibility of delisting if compliance is not regained or extended.
The most recent analyst rating on (NXL) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Nexalin Technology, Inc. stock, see the NXL Stock Forecast page.
More about Nexalin Technology, Inc.
Nexalin Technology, Inc. is a Houston-based medical technology company that designs and develops non-invasive neurostimulation devices aimed at addressing the global mental health crisis. Its bioelectronic medical products, including the Gen-2 15 milliamp Deep Intracranial Frequency Stimulation device, are intended to penetrate deep brain structures associated with mental health disorders and are designed to be undetectable to the human body, with regulatory approvals already secured in markets including China, Brazil, Oman and Israel.
Average Trading Volume: 211,542
Technical Sentiment Signal: Sell
Current Market Cap: $11.69M
See more data about NXL stock on TipRanks’ Stock Analysis page.